Companies /Healthcare

Teva- Pharmaceutical Industries Ltd

NYSE: TEVA Drug Manufacturers - Specialty & Generic
$39.23
▲ $0.69 (+1.79%) today
Markets closed · 8:14pm ET

24/7 Wall St. View

TEVA at a Glance

Valuation
Market cap
$45.8B
P/E ratio
91.2
Profitability
Revenue (TTM)
$17.2B
Profit margin
2.9%
EPS (TTM)
$0.43
Price
52-week range
$24 – $45
24/7 target
$52.21
Street target
$50.51

Headquartered in 124 Dvora Hanevi?a St., Tel Aviv-yafo Fiscal year ends December NYSE: TEVA tevapharm.com

About Teva

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company shifting toward innovative biopharmaceuticals under its Pivot to Growth strategy, backed by a large generics business.

**Innovative medicines.** Its portfolio focuses on neuroscience and immunology:
- AUSTEDO/AUSTEDO XR (deutetrabenazine) for tardive dyskinesia and Huntington's chorea.
- AJOVY (fremanezumab) for migraine prevention.
- UZEDY (risperidone LAI) for schizophrenia.
- WELTRUZA (olanzapine LAI), approved by the FDA in October 2026.
- Legacy brands COPAXONE and BENDEKA/TREANDA.

**Pipeline.** Late-stage assets include:
- Ecopipam for pediatric Tourette syndrome (NDA under FDA review).
- BXCL-501, acquired from BioXcel.
- Anti-IL-15 (TEV-'408) for celiac disease and vitiligo.
- Duvakitug (anti-TL1A), which generated development milestone payments.

**Generics and biosimilars.** Teva sells complex generics, OTC products and biosimilars, including TRUXIMA, SIMLANDI and DEGEVMA, and is expanding through partnerships such as Samsung Bioepis.

**Reporting structure.**
- Segments: United States, Europe, and International Markets (more than 35 countries, including Canada, Israel, Russia and Latin America).
- Other Activities: the Anda U.S. distribution business, third-party API sales (being divested), the Medis out-licensing platform, and contract manufacturing.

Teva's ordinary shares are listed directly on the NYSE and TASE. It regained an investment grade credit rating in 2026, and had total debt of $16.7 billion and net debt of $12.6 billion as of September 30, 2026. Updated

Latest Activity

52-week highs
43stocks hit new 52-week highs this week
  • MSIMotorola Solutions$530.42+7.7%
  • IBNICICI Bank$34.51+7.2%
  • EWEdwards Lifesciences$107.19+6.4%
  • TEVATeva$44.54+5.8%
  • FASTFastenal Company$55.55+4.4%
  • CAHCardinal Health$281.14+4.4%
  • MRNAModerna$223.37+4.1%
  • HUMHumana$450.47+3.9%
  • ICEIntercontinental Exchange$178.49+3.3%
  • KOCoca-Cola Company$99.26+3.3%

43 stocks notched fresh 52-week highs this week, with leadership spread across Motorola Solutions, ICICI Bank, Edwards Lifesciences, Coca-Cola, Humana and Fastenal. Motorola Solutions leads at $530.42, 7.7% past its prior peak.

Mad Money w/ Jim Cramer 11/11/26

  • Cramer says Nvidia leadership turmoil has made him gun shy on tech, yet writing off data center names risks big upside
  • CoreWeave CEO: compute demand 10 times oversubscribed for 2027, with chips recontracting at 20% to 50% premiums
  • Cramer would rather own Colgate or Johnson & Johnson than chase the noise right now
  • Caller questions on Darden's Olive Garden value proposition, Meta re-entry, and Jersey Mike's under Charlie Morrison

The tell is that four-year-old GPUs are being recontracted above their original prices, which undercuts the view that AI hardware depreciates into worthlessness. Cramer is keeping data center exposure in semis, networking, turbines and cooling even while trimming elsewhere, and he is leaning defensive with staples and pharma as the Nvidia story gets messier.

Now director at TEVA PHARMACEUTICAL INDUSTRIES LTD

Healthcare policy veteran David J. Brailer, the first U.S. National Coordinator for Health IT and a longtime Health Evolution investor, now sits inside the boardroom at the $50.9 billion generics maker. His first Form 3 starts the clock on every future buy or sell he makes, and boards rarely add that kind of policy firepower without a strategy shift in mind.

TEVATeva
52-week high
$42.99
+0.89%vs prior 52-week high · Nov 6, 2026

Teva's $42.99 close tops the high it set three sessions earlier by 0.89%, capping a climb from $24.26 a year ago. The generic drugmaker is now held by 40 ETFs, so the grind higher is lifting broad funds too.

Before the movelast 24 hours
  1. Earnings release
    Related company: TTWO

    TTWO Q2 2027 earnings filed

TEVATeva
Q3 2026
EPS
$0.86
est $0.73+17.8%
Revenue
$4.39B
est $4.24B+3.6%

Teva's innovative brands AUSTEDO, AJOVY and UZEDY grew 33% in local currency, offsetting the lenalidomide-driven slide in U.S. generics revenue. Both lines came in ahead of expectations, and management raised full-year revenue guidance to $16.7 to $17.0 billion.

Quarterly EPS — reported vs estimate

TEVA Coverage

Frequently Asked Questions

What does Teva do?

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company shifting toward innovative biopharmaceuticals under its Pivot to Growth strategy, backed by a large generics business. **Innovative medicines.** Its portfolio focuses on neuroscience and immunology: - AUSTEDO/AUSTEDO XR (deutetrabenazine) for…

What is the TEVA stock price target?

24/7 Wall St.'s 12-month price target for TEVA is $52.21, rated Buy. The Wall Street consensus target is $50.51. TEVA price prediction →